

## **MedBright AI Announces Beta Customer for MedMatrix, the AI-Driven Data and Analytics Platform**

Vancouver, British Columbia – December 7, 2023 – MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) is pleased to announce that the Dermatology Institute & Skin Care Center (“DISCC”), a leader in dermatologic services in Southern California, has chosen to implement MedMatrix to improve their clinic operations. MedMatrix is an industry leading AI-powered data analytics platform developed and operated by Healthcare Accretion AI, a Medbright AI investment. MedMatrix harnesses the power of artificial intelligence to evaluate and analyze key aspects of healthcare facilities, including patient needs and resource matching, revenue cycle management, patient demographics, facility geography, and competition. Through its advanced AI and data analytics capabilities, MedMatrix works alongside healthcare professionals to optimize each of these critical areas, resulting in more efficient clinic operations and improved patient outcomes.

DISCC specializes in cosmetic, medical, and surgical dermatology in Los Angeles. Led by board-certified dermatologist Paul Yamauchi, MD, PhD, the practice offers state-of-the-art dermatology services to provide the highest quality skin care possible. Dr. Yamauchi is a nationally recognized dermatologist and a key opinion leader in the subject of psoriatic, atopic dermatitis and other inflammatory skin disorders. In addition to his role as medical director for DISCC, he is also the medical director for Clinical Science Institute, the clinical assistant professor of dermatology for the David Geffen School of Medicine and an adjunct associate professor of the John Wayne Cancer Institute.

“There is clearly a need for AI to help operations and the efficiency of clinics,” Dr. Yamauchi said. “I’m excited to see the improvements we can make as a result of using the MedMatrix platform.”

Michael Dalsin, Chairman of Healthcare Accretion AI, said “We are pleased to have DISCC and Dr. Yamauchi as customers of the MedMatrix Platform, and are looking forward to showing the results of our early operations with DISCC in the coming months.”

### **About MedBright AI Investments Inc.**

MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at MedBright prides themselves on unparalleled access to opportunities, as well as structuring unique and advantageous investments. MedBright's mission is to construct a portfolio of synergistic investments to generate superior returns for shareholders. MedBright will focus on significant near-term and midterm high-quality opportunities with strong return potentials while maintaining commitment to governance.

MedBright AI Investments Inc.  
Alnoor Nathoo, Chief Executive Officer  
(587)-899-6967  
Email: [investors@medbright.ai](mailto:investors@medbright.ai)

## Cautionary Statement Regarding "Forward-Looking" Information

*This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation, the anticipated benefits of MedMatrix such as increased clinic revenue, enhanced patient satisfaction, reduced wait times and physician burnout, including with respect to its use by DISCC, and the Company's plans to generate returns for its shareholders through its portfolio of investments, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.*

*Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that MedMatrix will offer increased clinic revenue, enhanced patient satisfaction, reduced wait times and physician burnout, and that the Company will be able to generate returns for its shareholders. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the use of MedMatrix will not result in increased clinic revenue, enhanced patient satisfaction, or reduced wait times and physician burnout, and the risk that the Company's portfolio of investments will not generate returns for shareholders.*

*Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.*